A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200 Following a Single Oral Dose in Healthy Male Subjects
Latest Information Update: 01 Sep 2022
At a glance
- Drugs PBI-200 (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Pyramid Biosciences
Most Recent Events
- 24 Aug 2022 Status changed from recruiting to completed.
- 16 Feb 2022 New trial record